83871-05-0

Upstream product

• 69470-09-3 N-tert-butyloxycarbonyl-L-phenylalanyl-L-proline amide 
• 83871-06-1 N-benzyloxycarbonyl-L-phenylalanyl-L-prolinamide 
• 1161-13-3 N-Cbz-L-Phe 
• 50903-54-3 N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanine pentafluorophenyl ester 
• 7531-52-4 L-prolinamide 

Downstream Products

• 88888-75-9 N-(benzyloxycarbonyl)-L-γ-methylglutamyl-L-phenylalanyl-L-prolinamide 
• 77020-18-9 bromoacetylphenylalanylproline amide 
• 81500-70-1 4-chloroacetylbenzoyl-L-Phe-L-Pro-NH₂ 
• 81500-69-8 3-chloroacetylbenzoyl-L-Phe-L-Pro-NH₂ 
• 69461-91-2 Z-pGlu-Phe-Pro-NH₂ 
• 34783-35-2 L-pyroglutamyl-L-phenylalanine-L-proline amide 
• 77020-12-3 4-Guanidino-benzoic acid [(S)-1-benzyl-2-((S)-2-carbamoyl-pyrrolidin-1-yl)-2-oxo-ethylcarbamoyl]-methyl ester 
• 74135-04-9 morphiceptin 

Relevant academic research and scientific papers

Synthesis of Thyrotropin-Releasing Hormone Analogues. 1. Complete Dissociation of Central Nervous Effects from Thyrotropin-Releasing Activity

Twenty-four thyrotropin-releasing hormone (TRH) analogues containing mainly aliphatic amino acids in position 2 were synthesized and tested for central nervous system (CNS) and hormonal (TSH) activity.Application of the pentafluorophenyl ester method in t

Potential thyroliberin affinity labels. II: Chloroacetyl substituted phenylalanyl prolineamides

Three analogs of thyroliberin (I) were prepared. These compounds, N-m-chloroacetylbenzoyl-phenylalanyl-prolineamide (VIa), N-p-chloroacetylbenzoyl-phenylalanyl-prolineamide (VIb) and N-chloroacetyl-alanyl-phenylalanyl-prolineamide (IX), were designed as potential I antagonist affinity labels. However, no significant antagonist activity was observed. Compounds VIa and IX were found to have weak agonist activity. Cyclo (Phe-Pro) an analog of the I metabolite, cyclo (His-Pro), was found, however, to have significant I antagonist activity, but no agonist activity.